Health Canada to keep importing Kaleo's epinephrine shot amid shortages

Article content

The Canadian health regulator said on Friday it would keep importing U.S.-based Kaleo Inc’s epinephrine auto-injectors and expects adequate supply of the devices in the country over the coming months.

There has been a shortage of EpiPens in the United States, Europe and Canada, mainly hit by a series of manufacturing delays at Pfizer’s Meridian Medical unit that produces all EpiPens sold globally at a single plant near St. Louis.

We apologize, but this video has failed to load.

tap here to see other videos from our team. Try refreshing your browser, or Health Canada to keep importing Kaleo's epinephrine shot amid shortages Back to video

Health Canada’s announcement comes after Pfizer Inc, which makes Mylan NV’s EpiPen, notified the regulator that a shortage of the 0.3 mg dose of the emergency allergy shots may lead to temporary supply constraints in Canada.
